Trial profile. Safety and efficacy intent-to-treat population includes the 55 patients enrolled in the study. One patient on screening had HGBCL with MYC rearrangement, but was negative for BCL2 by immunohistochemistry and FISH. HGBCL, high-grade B-cell lymphoma.